Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of praliciguat in adults diagnosed with biopsy-confirmed focal segmental glomerulosclerosis FSGS, a kidney disease. This Phase 2, randomized, double-blind, placebo-controlled, multicenter study compares praliciguat to a placebo over an initial 24-week period, followed by an open-label phase where all participants receive praliciguat for another 24 weeks. Those who respond to treatment may join a long-term safety extension study. Participants are randomly assigned to receive either praliciguat or a matching placebo daily during the 24-week double-blind period. After this, all participants take praliciguat daily during the 24-week open-label period. Dose escalation to a target dose occurs during the initial treatment phase. Responders are invited to continue in a long-term safety extension where praliciguat is administered daily. During the study, participants undergo regular assessments including urine protein-to-creatinine ratio UPCR measurements, monitoring for treatment-emergent adverse events, and plasma concentration tests of praliciguat. Safety is closely tracked through reports of adverse events during both treatment periods and the long-term extension. The total participation duration may extend up to more than 48 weeks depending on extension study enrollment.
Actively Recruiting
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.